Telehealth Weight Loss/GLP-1 Prescribing: What Psychiatrists Can Do in Georgia

If you’re a psychiatrist or psychiatric nurse practitioner watching the GLP-1 revolution unfold, you’ve probably asked yourself: Can I prescribe these medications? Should I?

The short answer: Yes, in most cases — but the details matter more than you think.

Weight loss medications, especially GLP-1 agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro), have exploded in popularity. Your patients are asking about them. Many are already on them. And the intersection of metabolic health and mental health means psychiatric providers are uniquely positioned to help — if you understand the legal landscape and clinical rationale.

This isn’t about chasing a trend. It’s about recognizing that obesity and psychiatric conditions are deeply connected: medication-induced weight gain from antipsychotics, emotional eating tied to depression, metabolic syndrome complicating ADHD treatment. If you’re already managing a patient’s brain chemistry, why wouldn’t you address their metabolic health when it directly impacts outcomes?

But here’s the catch: prescribing weight loss medications comes with a maze of state-specific regulations, scope-of-practice debates, telehealth restrictions, and reimbursement complexities that most psychiatrists and PMHNPs weren’t trained to navigate.

This guide cuts through the noise. We’ll cover:

• Whether psychiatrists and PMHNPs can legally prescribe GLP-1s and other weight loss drugs
• State-by-state prescribing authority (especially California, Texas, Florida, New York, Pennsylvania, and Illinois)
• Telehealth prescribing rules — including which states ban controlled substance prescriptions remotely
• Clinical scope considerations: When it makes sense for a psychiatric provider to treat obesity, and when it doesn’t
• Reimbursement landscape: What insurance covers, what you can bill, and why this might be more lucrative than you think

Let’s get into it.

Can Psychiatrists Prescribe Weight Loss Medications?

Yes. Psychiatrists have full prescriptive authority in all 50 states.

As licensed physicians (MD or DO), you can prescribe FDA-approved weight loss medications — GLP-1 agonists, phentermine, combination drugs like Contrave — just as you can prescribe SSRIs or antipsychotics. There’s no special certification required at the federal level.

But before you start writing scripts, let’s talk about the should question.

Is Weight Management Within a Psychiatrist’s Scope of Practice?

This is where things get interesting. Traditionally, psychiatrists stick to psychiatric medications. Weight management falls under endocrinology or primary care, right?

Not necessarily.

Dr. Elliott Lewis, a board-certified psychiatrist and obesity medicine specialist, argues that managing obesity is a logical extension of psychiatric care:

‘If we truly understand that metabolic and mental health systems are inseparable, then psychiatrists being involved in metabolic treatment makes complete sense.’

Consider this:

• Many psychiatric medications cause weight gain (antipsychotics, mood stabilizers, some antidepressants). You’re already monitoring metabolic side effects — checking glucose, lipids, weight.
• Obesity worsens mental health outcomes. Depression, anxiety, and self-esteem issues compound when patients struggle with weight.
• GLP-1s may have psychiatric benefits. Early research suggests they reduce cravings, improve mood scores, and might help with binge eating or substance use disorders (though this use is still experimental).

So prescribing a weight loss medication for a patient who gained 40 pounds on Seroquel? That’s not ‘scope creep’ — that’s comprehensive care.

The key is competency. Just like you wouldn’t prescribe lithium without understanding therapeutic levels and monitoring, you shouldn’t prescribe semaglutide without understanding GLP-1 pharmacology, contraindications, and monitoring protocols.

Many psychiatrists are pursuing American Board of Obesity Medicine (ABOM) certification to formalize this expertise. It requires about 60 hours of CME in obesity science and passing an exam — doable, and it positions you to confidently manage metabolic health alongside psychiatric treatment.

What About Safety? The Suicidality Scare

You’ve probably seen headlines about GLP-1s and suicide risk. Let’s clear this up with actual data:

A 2025 meta-analysis in JAMA Psychiatry found no increase in depression or suicidal ideation with GLP-1 medications versus placebo. In fact, GLP-1-treated groups showed slightly lower rates of depressive symptoms in clinical trials.

Both the FDA and European Medicines Agency reviewed the data and found no causal link between GLP-1s and suicidal behavior.

That said, you should still monitor patients closely — not because the drugs cause psychiatric issues, but because weight loss can trigger body image struggles, and patients with pre-existing depression deserve careful follow-up. That’s actually an argument for psychiatric providers managing these medications, not against it.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Can PMHNPs Prescribe Weight Loss Medications?

It depends entirely on your state.

Psychiatric Nurse Practitioners face a patchwork of regulations. Some states grant full prescriptive authority; others require physician collaboration or supervision. And some states have specific rules that complicate weight loss prescribing even if you have broad authority.

The State-by-State Reality

As of 2026, about 24 states grant Full Practice Authority (FPA) to nurse practitioners, meaning you can prescribe independently. The rest require some level of physician involvement.

But even in FPA states, there are wrinkles:

In ‘independent’ states like Washington or New Mexico, you can legally prescribe GLP-1s without a collaborating physician. However, many insurers and pharmacies still request physician sign-off for high-cost medications, especially for prior authorizations. It’s not a legal requirement, but it’s a practical barrier.

In collaborative states like Texas or Florida, you must have a written agreement with a physician to prescribe anything. Texas requires a Prescriptive Authority Agreement that explicitly lists what you can prescribe (including weight loss drugs). Florida requires a protocol agreement with a supervising MD or DO, and even NPs with ‘autonomous practice’ status (limited to primary care NPs, not psychiatric) cannot prescribe controlled substances independently.

In states like Pennsylvania and New York, you need a collaborative agreement initially, but experienced NPs (3,600+ hours in NY, for example) can transition to more independence — though prescribing weight loss medications still requires the agreement to cover those drugs.

Here’s the bottom line: If you’re a PMHNP, check your state’s Nurse Practice Act and ensure your collaborating physician (if required) explicitly authorizes weight loss medication prescribing in your agreement.

Does Weight Loss Fall Within a PMHNP’s Scope?

This is where things get gray. PMHNPs are trained in psychiatric assessment and psychotropic medication management — not metabolic disorders or obesity medicine.

However, scope of practice is defined by competency, not just your certification focus. If you pursue additional training in obesity management (CME courses, mentorship, or even obesity medicine certification), you can expand your scope.

Many PMHNPs justify weight loss prescribing by framing it as managing medication side effects. If a patient gained weight from Zyprexa or Abilify, prescribing metformin or a GLP-1 to counteract that is arguably within your psychiatric scope — you’re mitigating iatrogenic harm.

Starting a standalone weight loss clinic for the general public? That’s trickier. Some state boards might question whether you’re practicing outside your specialty. The safest approach: integrate weight management into your existing psychiatric practice, and ensure any collaborative physician is on board.

State-Specific Rules: Where It Gets Complicated

Let’s break down the six priority states where most telehealth providers operate.

California

NP Status: Restricted → Transitioning to Full Practice Authority (2026)
California’s AB 890 is phasing in NP independence. After 3 years/4,600 hours of supervised practice, NPs can practice without physician oversight. Full implementation begins January 1, 2026.

The Catch: California’s Corporate Practice of Medicine (CPOM) doctrine is strict. Even independent NPs can’t own medical practices or clinics — only physicians can. You’ll need to operate within a physician-owned entity or MSO structure.

Prescribing: Psychiatrists can prescribe weight loss meds freely. NPs can prescribe under standardized procedures now; once independent (2026), they won’t need MD permission for non-controlled drugs. But controlled substances (like phentermine) still require physician protocols until full FPA.

Telehealth: No state restrictions on prescribing via telemedicine. Telehealth parity law ensures equal reimbursement.

Texas

NP Status: Restricted (Collaboration Required)
Texas is one of the strictest states. All NPs must have a Prescriptive Authority Agreement with a Texas-licensed physician to prescribe anything. The agreement must detail supervision, monthly quality reviews, and chart audits.

Prescribing: Psychiatrists can prescribe weight loss drugs, but Schedule II stimulants (amphetamines) are prohibited for weight loss. Phentermine (Schedule IV) is allowed. NPs can prescribe weight meds only if explicitly authorized in their PAA.

Telehealth: Texas allows telemedicine prescribing if the standard of care is met. Federal waivers (extended through 2025) permit controlled substance prescribing via telehealth without an initial in-person exam. However, you must check the Texas Prescription Monitoring Program (PMP) before prescribing controlled drugs.

Corporate Practice: Only physicians can own medical practices. Non-physician-owned clinics use MSO models and physician oversight.

Florida

NP Status: Restricted (Supervision Required)
Florida APRNs must have a written protocol with a supervising physician. ‘Autonomous practice’ exists but is limited to primary care NPs (not psychiatric) and excludes controlled substance prescribing.

Prescribing: Florida has some of the strictest weight loss regulations in the country:

• Initial in-person exam required (or equivalent full evaluation, which can be delegated to an APRN/PA but must be documented)
• Patients must have BMI ≥30 or ≥25 with comorbidity
• Written informed consent required
• Follow-up visits every 3 months minimum
• Must provide patients with Florida’s ‘Weight-Loss Consumer Bill of Rights’

Telehealth Restriction: Florida law prohibits prescribing controlled substances via telehealth for weight loss. The only exceptions are psychiatric treatment, inpatient/hospice care, or addiction medicine. This means you cannot prescribe phentermine via telemedicine to Florida patients under state law. GLP-1s (non-controlled) are fine via telehealth as long as you meet the clinical standards.

Clinic Rules: Any weight loss clinic must register under Florida’s Health Care Clinic Act and have a Florida-licensed physician as medical director.

New York

NP Status: Reduced Practice → Full Practice After 3,600 Hours
New York NPs start with a collaborative agreement but can practice independently after 3,600 hours (~2 years full-time). Most experienced PMHNPs in NY operate independently.

Prescribing: No state-specific obesity prescribing rules. Standard of care applies (document BMI, indications, informed consent). You must check the I-STOP Prescription Monitoring Program before prescribing any Schedule II-IV controlled substances.

Telehealth: Very permissive. No state restrictions on controlled substance prescribing beyond federal rules. Telehealth payment parity law (2022) ensures equal reimbursement for video visits.

Market: NYC is saturated with weight loss clinics, but upstate and rural areas are underserved.

Pennsylvania

NP Status: Reduced Practice (Collaboration Required)
All CRNPs must have a Collaboration Agreement with a physician. The physician doesn’t need to be on-site but must review charts and be available for consultation. No FPA legislation has passed yet (though it’s been proposed repeatedly).

Prescribing: No specific state rules for weight loss drugs. The collaborative agreement must authorize controlled substance prescribing if you’re using phentermine.

Telehealth: Pennsylvania permits telemedicine. No extra state restrictions on controlled substance prescribing. Telehealth reimbursement for mental health is mandated (Act 69, 2020), but full parity for all services isn’t yet law.

Illinois

NP Status: Partial Full Practice Authority
Illinois allows APRNs to achieve Full Practice Authority after ≥4,000 hours of clinical experience and ≥250 hours of continuing education. FPA-APRNs can prescribe independently, including controlled substances (with some consulting requirements for Schedule II in the first year).

Prescribing: No state-specific obesity rules. Illinois requires a separate Controlled Substance license for any prescriber.

Reimbursement: Illinois Medicaid reimburses APRNs at 100% of physician rates — a huge financial incentive.

Telehealth: Strong parity laws. No state restrictions on controlled substance prescribing via telemedicine.

Telehealth Prescribing: Federal vs. State Rules

This is where many providers get tripped up.

Federal Law: Ryan Haight Act Waivers

Historically, the Ryan Haight Act required an in-person exam before prescribing controlled substances. During COVID, the DEA waived this requirement. That waiver has been extended multiple times — most recently through December 31, 2025.

As of 2026, you can prescribe controlled substances (including phentermine for weight loss) via telemedicine without an initial in-person exam — at the federal level.

But State Law Can Override Federal Waivers

Here’s the trap: even if the DEA allows it, state medical boards can impose stricter rules.

Florida prohibits controlled substance prescribing via telehealth except for psychiatric treatment (which weight loss arguably isn’t). Alabama requires an in-person exam for any controlled substance. Mississippi and South Carolina have similar restrictions.

About 8 states have telemedicine prescribing restrictions stricter than current federal law. If you’re practicing via telehealth, you need to check both federal and state rules for every state where you’re licensed.

Practical Implications

If you’re on a platform like Klarity:

• GLP-1 agonists (semaglutide, tirzepatide) are NOT controlled substances and can be prescribed via telehealth in all states (as long as you meet clinical standards)
• Phentermine (Schedule IV) can be prescribed via telehealth in most states, but not Florida or Alabama
• Always check your state’s Prescription Monitoring Program (PMP) before prescribing controlled drugs

Reimbursement: Is This Financially Viable?

Let’s talk money. Because if you’re going to add weight management to your practice, it needs to make economic sense.

Insurance Coverage Is Expanding Fast

A few years ago, most insurers didn’t cover weight loss drugs. That’s changing:

• GLP-1 medications like Wegovy are now covered by many commercial plans (with prior authorization)
• Medicare announced in late 2025 that it will begin covering anti-obesity medications — a game-changer for senior patients
• State Medicaid programs are following suit

Prior authorizations typically require:

• BMI ≥30 (or ≥27 with comorbidity)
• Documentation of lifestyle interventions (diet, exercise)
• Sometimes proof of previous weight loss attempts

Insurers may also impose quantity limits — for example, some plans only approve 30-day supplies initially to monitor adherence.

What Can You Bill?

For the clinical visit, you use standard E/M codes (99202-99215) or psychiatric evaluation codes. If you’re combining weight management with a psychiatric follow-up, document both issues and code for the complexity.

There are also obesity counseling codes (G0447 for 15-minute face-to-face counseling, G0473 for group sessions), though these are typically used by primary care or dietitians.

Telehealth parity laws in California, New York, Illinois, and Pennsylvania ensure that video visits are reimbursed at the same rate as in-person visits.

Psychiatrists vs. PMHNPs: Reimbursement Rates

• Psychiatrists are reimbursed at 100% of the physician fee schedule
• PMHNPs typically receive 85% of the physician fee from Medicare (and similar percentages from private insurers)
• Exception: Illinois Medicaid pays APRNs at 100% of physician rates

A typical 15-20 minute med management visit might reimburse:

• Medicare: $75-$150 depending on code and region
• Commercial insurance: Often higher

The Cash-Pay Market

Many patients are accessing GLP-1s through cash-pay telehealth services (monthly memberships or per-consultation fees). This bypasses insurance hassles but limits your market to patients who can afford out-of-pocket costs (Wegovy costs ~$1,300/month without insurance).

As insurance coverage expands, more patients will go the covered route — which is better for patient access and your volume.

Prescribing Protocols and Compliance: Don’t Skip This

Even if you have the legal authority to prescribe, you need to follow clinical standards — both for patient safety and to avoid regulatory scrutiny.

Documentation Essentials

At minimum, document:

• BMI and weight history
• Comorbidities (diabetes, hypertension, sleep apnea)
• Previous weight loss attempts (diet, exercise, other medications)
• Psychiatric history and current medications (especially if you’re prescribing)
• Contraindications (e.g., personal or family history of medullary thyroid cancer for GLP-1s)
• Informed consent (risks, benefits, alternatives)
• Monitoring plan (follow-up schedule, lab work if needed)

Some states (like Florida, New Jersey, Virginia) have specific prescribing rules that mandate certain elements — BMI thresholds, consent forms, follow-up frequency. Review your state’s medical board guidelines.

State-Specific Protocol Requirements

Florida:

• In-person or comprehensive telehealth exam before first prescription
• BMI ≥30 or ≥27 with comorbidity
• Written informed consent
• Provide ‘Weight-Loss Consumer Bill of Rights’
• Follow-up every 3 months minimum
• Check PMP (E-FORCSE) for controlled substances

New Jersey:

• Comprehensive physical exam (or equivalent telehealth assessment)
• Psychiatric screening prior to or alongside weight loss treatment
• Nutritional counseling, exercise, and behavior modification must be provided or arranged (not just pills)

Virginia:

• Follow-up within 30 days of starting medication, then monthly initially
• Document diet and exercise plan

Compounded Semaglutide: Proceed with Caution

Some telehealth clinics use compounded semaglutide to offer cheaper options. Regulators are cracking down:

• Alabama’s Board of Medical Examiners warned that using non-FDA-approved semaglutide salts (like semaglutide sodium) from unregistered facilities is prohibited
• Mississippi banned off-label GLP-1 prescribing for weight loss (must use FDA-approved obesity versions like Wegovy, not diabetes versions like Ozempic, unless treating diabetes)

If you prescribe compounded medications, ensure:

• The pharmacy is a registered outsourcing facility (FDA 503B)
• The compound uses FDA-sanctioned ingredients
• There’s a legitimate shortage justification (FDA’s guidance on compounding during drug shortages)

You could face liability if patients receive substandard or contaminated compounds.

When Should Psychiatrists and PMHNPs Prescribe Weight Loss Meds?

Not every patient is a fit. Here’s how to think about it:

Good Candidates for Psych Provider Weight Management:

✅ Patients with medication-induced weight gain
If they gained weight from antipsychotics, mood stabilizers, or antidepressants, addressing that metabolically is part of treating side effects.

✅ Patients with co-occurring psychiatric and metabolic conditions
Depression + obesity. ADHD + binge eating. Anxiety + metabolic syndrome. Treating both makes sense.

✅ Patients who trust you and are already engaged in psychiatric care
You have a relationship. You understand their whole picture. Adding metabolic support is a natural extension.

✅ Patients in underserved areas with limited access to primary care
If you’re their main prescriber, helping with weight management might be the most practical option.

When to Refer Out:

❌ Patients with complex endocrine disorders (uncontrolled thyroid disease, Cushing’s syndrome)
These need specialist workup.

❌ Patients with significant cardiovascular disease or renal impairment
GLP-1s are generally safe but require careful monitoring. Coordinate with cardiology or nephrology.

❌ Patients seeking weight loss as a primary goal with no psychiatric component
If you’re advertising a weight loss clinic and seeing patients solely for that, you’re arguably practicing outside your specialty — unless you’ve pursued additional training/certification in obesity medicine.

❌ Patients where you don’t have the bandwidth to monitor appropriately
Weight management requires follow-up (monthly initially, then quarterly). If your schedule is packed with acute psychiatric cases, adding weight management might stretch you too thin.

The Business Case: Why Platforms Like Klarity Make Sense

Let’s be real: starting your own weight loss telehealth practice is a lot of work.

You’d need to:

• Handle marketing (which is expensive — acquiring a qualified psychiatric patient through DIY marketing typically costs $200-$500+ when you factor in ad spend, SEO time, agency fees, and lead qualification)
• Build telehealth infrastructure
• Navigate 50 different state regulations
• Credential with insurers (or build a cash-pay model)
• Manage billing and collections
• Handle prior authorizations for GLP-1s (which are notoriously bureaucratic)

Or you can join a platform like Klarity that handles all of that for you.

Here’s why it makes economic sense:

Traditional Marketing vs. Klarity’s Model

DIY Marketing Reality:

• SEO: Takes 6-12 months of consistent investment before generating patient flow. Most solo providers don’t have the expertise or patience.
• Google Ads: Mental health keywords cost $15-40+ per click. Most clicks don’t convert to booked patients. Realistic cost per booked patient: $200-400+.
• Directory listings (Psychology Today, Zocdoc): Monthly fees plus per-booking charges. Zocdoc charges $35-100+ per booking, and you’re competing with hundreds of other providers on the same page.
• Total monthly marketing spend for a solo practice: Easily $3,000-5,000/month with uncertain results.

Klarity’s Model:

• No upfront marketing spend
• No monthly subscription fees
• Pre-qualified patients already matched to your specialty and availability
• You only pay when a patient books with you (similar to Zocdoc’s per-appointment model, but with a standard listing fee per new patient lead)
• Built-in telehealth infrastructure (no separate platform costs)
• Both insurance and cash-pay patient flow
• You control your schedule

The Economic Trade-Off:
Instead of gambling $3,000-5,000/month on marketing with uncertain ROI, you pay only when you see patients. That’s guaranteed ROI — you know exactly what your patient acquisition cost is, and you only pay for patients who show up.

For most providers, especially those starting out or scaling, this is a no-brainer.

What About Long-Term?

Some providers worry: ‘If I build my practice on a platform, am I just renting patients?’

Fair question. But consider:

• Year 1-2: You’re building your patient panel, generating income, and learning what works — without the financial risk of marketing spend.
• Year 3+: You have cash flow to invest in your own marketing if you want to scale independently. Many providers stay on platforms because the economics still make sense.

The alternative — spending $50,000+ on marketing in your first year with no guarantee of results — is how most practices fail.

FAQ: Weight Loss Prescribing for Psychiatrists and PMHNPs

Q: Can psychiatrists prescribe GLP-1 medications like Ozempic or Wegovy?
A: Yes. Psychiatrists have full prescriptive authority in all 50 states and can prescribe FDA-approved weight loss medications, including GLP-1 agonists.

Q: Do I need special certification to prescribe weight loss drugs?
A: No legal requirement, but pursuing American Board of Obesity Medicine (ABOM) certification strengthens your scope of practice and clinical competency.

Q: Can PMHNPs prescribe weight loss medications independently?
A: It depends on your state. About 24 states grant full practice authority. Others require physician collaboration. Check your state’s Nurse Practice Act and ensure your collaborative agreement (if required) explicitly authorizes weight loss prescribing.

Q: Can I prescribe weight loss medications via telehealth?
A: Generally yes, but state rules vary. GLP-1s (non-controlled) can be prescribed via telehealth in all states. Controlled substances like phentermine can be prescribed via telehealth in most states due to federal waivers (extended through 2025), but some states (Florida, Alabama) prohibit it.

Q: Are GLP-1 medications covered by insurance?
A: Increasingly, yes. Many commercial plans cover Wegovy and similar drugs with prior authorization. Medicare announced in late 2025 it will begin covering anti-obesity medications. Medicaid coverage varies by state.

Q: What can I bill for weight management visits?
A: Use standard E/M codes (99202-99215) or psychiatric evaluation codes. Telehealth visits are typically reimbursed at parity with in-person visits in states like California, New York, Illinois, and Pennsylvania.

Q: What are the main compliance risks?
A: Not following state-specific prescribing rules (e.g., Florida’s mandatory 3-month follow-ups), prescribing controlled substances via telehealth in states that prohibit it, and using non-FDA-approved compounded medications.

Q: How do I know if weight management is within my scope of practice?
A: If you’re managing medication side effects (e.g., antipsychotic-induced weight gain) or treating obesity in patients with co-occurring psychiatric conditions, it’s arguably within your scope. If you’re seeing patients solely for weight loss with no psychiatric component, consider additional training or certification.

Q: What’s the best way to start offering weight management services?
A: Integrate it into your existing psychiatric practice first — focus on patients where metabolic and mental health overlap. Pursue CME in obesity management. Join a platform like Klarity that handles patient acquisition, credentialing, and compliance infrastructure so you can focus on clinical care.

Q: Are GLP-1s safe from a psychiatric standpoint?
A: Yes. A 2025 meta-analysis found no increase in depression or suicidality with GLP-1 medications versus placebo. Regulatory agencies (FDA, EMA) found no causal link to psychiatric adverse events.

Q: What monitoring do I need to do for patients on GLP-1s?
A: Initial labs (glucose, lipids, kidney function), regular weight and vital signs checks, monitoring for GI side effects (nausea, vomiting), and psychiatric assessment (mood, suicidal ideation) — which you’re already equipped to do as a psychiatric provider.

The Bottom Line

Psychiatrists and PMHNPs can prescribe weight loss medications in most states — and in many cases, they should.

The overlap between metabolic health and mental health is undeniable. Addressing both isn’t scope creep; it’s comprehensive care. But you need to:

✅ Understand your state’s prescribing authority and telehealth rules
✅ Follow clinical protocols and document appropriately
✅ Pursue additional training if you’re making weight management a significant part of your practice
✅ Choose the right business model — platforms like Klarity remove the marketing risk and compliance headaches so you can focus on patient care

The weight loss medication market is exploding. Insurance coverage is expanding. Patients need providers who understand both the metabolic and psychiatric sides of obesity.

If you’ve been on the fence about adding weight management to your practice, now is the time to explore it — with your eyes open to the regulations, and the right infrastructure to support you.

Ready to expand your practice without the marketing gamble? Explore how Klarity connects psychiatrists and PMHNPs with pre-qualified patients — no upfront spend, no monthly fees, just pay-per-appointment simplicity.

Sources

1. Medical Director Co. – ‘How Much Does a Collaborative Physician Cost for Weight Loss, Telehealth, and Medspas? (2025 Definitive Guide)’ (www.medicaldirectorco.com) – 2025

2. Medical Director Co. – ‘Florida Weight Loss Clinic and Telehealth Compliance Guide (2025)’ (www.medicaldirectorco.com) – Updated 2025

3. Medical Director Co. – ‘Texas Weight Loss Clinic & Telehealth Compliance Guide (2025)’ (www.medicaldirectorco.com) – Updated 2025

4. Florida Administrative Code Rule 64B15-14.004 – ‘Standards for Prescription of Obesity Drugs’ (www.law.cornell.edu) – Effective August 8, 2022

5. Mondaq (Foley & Lardner LLP) – ‘A Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs’ (www.mondaq.com) – July 24, 2023

6. RxAgent.co – ‘Federal Permission, State Prohibition: The 2026 Telehealth Compliance Trap’ (rxagent.co) – December 16, 2025

7. The Nurse Practitioner Journal (Susanne J. Phillips, DNP, RN, FNP-BC, FAANP, FAAN) – ’36th Annual APRN Legislative Update: Improving Access to Healthcare’ (journals.lww.com) – January 2024

8. Dr. Elliott Lewis – ‘Should Psychiatrists Prescribe GLP-1 Medications? An Evidence-Based Perspective’ (drlewis.com) – January 4, 2026

9. Dr. Elliott Lewis – ‘GLP-1 Medications and Mental Health: Separating Facts from Fiction’ (drlewis.com) – November 26, 2025

10. Axios – ‘COVID-era telehealth prescribing extended again for Adderall and other controlled substances’ (www.axios.com) – November 18, 2024

11. Axios – ‘Trump announces Medicare coverage for weight-loss drugs’ (www.axios.com) – November 6, 2025

12. TheraThink – ‘Insurance Reimbursement Rates for Psychiatrists [2026 Updated Guide]’ (therathink.com) – 2026

13. Blue Cross Blue Shield of Texas – ‘Pharmacy Supply Limit for GLP-1 Medications Used for Obesity’ (www.bcbstx.com) – October 4, 2024

Source:

• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=The%20answer%20is%20almost%20always,yes
• https://www.medicaldirectorco.com/collaborative-physician-cost-weight-loss-telehealth/#:~:text=Nurse%20Practitioners%20
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Pennsylvania%20BON%20grants%20CRNPs%2C,more%20physicians%20to%20deliver%20healthcare
• https://journals.lww.com/tnpj/fulltext/2024/01000/36thannualaprnlegislativeupdate__improving.6.aspx#:~:text=The%20Illinois%20Department%20of%20Financial,collaborative%20agreement%20following%20a%20TTP
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=The%20DEA%20gave%20us%20the,evaluation%20at%20the%20federal%20level
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=Despite%20federal%20DEA%20waivers%20extending,traps%20for%20digital%20health%20providers
• https://rxagent.co/blog/telehealth-compliance-trap#:~:text=1.%20Florida%3A%20The%20%22No,for%20Stimulants
• https://www.mondaq.com/unitedstates/healthcare/1447512/a-changing-regulatory-and-reimbursement-landscape-for-weight-loss-drugs#:~:text=New%20Jersey%20law%20requires%20that,and%20identify%20the%20risks%20associated
• https://drlewis.com/glp-1-medications-psychiatry/#:~:text=You%20know%20these%20drugs,disorders%2C%20and%20possibly%20depression%20itself
• https://drlewis.com/glp-1-mental-health/#:~:text=Now%20let%E2%80%99s%20talk%20about%20potential,where%20things%20get%20really%20interesting